SOSorcha O'BYrne

Sorcha O'BYrne

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sorcha O'BYrne has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A :: AFF1 infant leukemia

    by Rebecca E. Ling, Alia M. N. Welsh, Lucy Hamer, Thomas Jackson, Emily Neil, Natalina Elliott, Joe W. Cross, Arundhati Wuppalapati, Alastair Smith, Catherine Chahrour, et al.

    Infant acute lymphoblastic leukemia (iALL) is initiated in utero, most often by rearrangements of the KMT2A gene (KMT2Ar). It carries a very poor prognosis despite a lack of additional oncogenic driver mutations common in childhood ALL. Here, we aimed to identify specific properties of human fetal hematopoietic stem/progenitor cells (HSPC) that promote leukemic transformation in KMT2Ar iALL using molecular, functional, and in vivo assays. Through comparison of human fetal HSPC with adult HSPC transcriptomes we derived a fetal development–specific gene signature and identified the fetal oncogene LIN28B and its downstream effectors among the top hits. These genes were also expressed in iALL. Functional assays revealed that LIN28B was essential in normal human fetal liver (FL) CD34+ cells to maintain proliferation and stem-like properties, and support B-cell and natural killer cell lymphopoiesis. To interrogate the role of LIN28B in iALL, we used a human FL-derived CRISPR–CRISPR-associated protein 9 KMT2A::AFF1 model. In this CRISPRKMT2A::AFF1 model, human FL CD34+ cells fail to transform upon induction of KMT2A::AFF1 translocation in the absence of LIN28B. Furthermore, LIN28B-expressing CRISPRKMT2A::AFF1 leukemias were more proliferative in vitro and in vivo, with this advantage being lost upon LIN28B knockdown. Mechanistic studies showed that LIN28B acts by stabilizing key early B-lymphoid genes, epigenetic regulators, and cell cycle and antiapoptotic genes. Thus, LIN28B has an essential role in normal human fetal B-lymphopoiesis and is necessary for initiation of KMT2A::AFF1 iALL in human fetal cells in the absence of cooperating mutations. LIN28B activity contributes to the aggressive behavior of KMT2A::AFF1 ALL, making it an attractive target in LIN28B-expressing leukemias.


  • Open Access

    CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    by Clara Bueno, Susana Barrera, Alex Bataller, Valentín Ortiz-Maldonado, Natalina Elliot, Sorcha O’bYrne, Guanlin Wang, Montse Rovira, Francisco Gutierrez-Agüera, Juan L. Trincado, et al.

    CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, which, coupled with the early onset of CD22 expression during B-cell development, suggests that preexisting CD34+CD22+CD19− (pre)-leukemic cells represent an “early progenitor origin-related” mechanism underlying phenotypic escape to CD19-directed immunotherapies. We demonstrate that CD22 expression precedes CD19 expression during B-cell development. CD34+CD19−CD22+ cells are found in diagnostic and relapsed bone marrow samples of ∼70% of patients with B-ALL, and their frequency increases twofold in patients with B-ALL in CR after CD19 CAR T-cell therapy. The median of CD34+CD19−CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling revealed that CD34+CD19−CD22+ cells harbor the genetic abnormalities present at diagnosis and initiate leukemogenesis in vivo. Our data suggest that preleukemic CD34+CD19−CD22+ progenitors underlie phenotypic escape after CD19-directed immunotherapies and reinforce ongoing clinical studies aimed at CD19/CD22 dual targeting as a strategy for reducing CD19− relapses. The implementation of CD34/CD19/CD22 immunophenotyping in clinical laboratories for initial diagnosis and subsequent monitoring of patients with B-ALL during CD19-targeted therapy is encouraged.


  • Open Access

    Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia

    by Eleni Louka, Benjamin Povinelli, Alba Rodriguez-Meira, Gemma Buck, Wei Xiong Wen, Guanlin Wang, Nikolaos Sousos, Neil Ashley, Angela Hamblin, Christopher A.G. Booth, et al.

    Juvenile myelomonocytic leukemia (JMML) is a poor-prognosis childhood leukemia usually caused by RAS-pathway mutations. The cellular hierarchy in JMML is poorly characterized, including the identity of leukemia stem cells (LSCs). FACS and single-cell RNA sequencing reveal marked heterogeneity of JMML hematopoietic stem/progenitor cells (HSPCs), including an aberrant Lin−CD34+CD38−CD90+CD45RA+ population. Single-cell HSPC index-sorting and clonogenic assays show that (1) all somatic mutations can be backtracked to the phenotypic HSC compartment, with RAS-pathway mutations as a “first hit,” (2) mutations are acquired with both linear and branching patterns of clonal evolution, and (3) mutant HSPCs are present after allogeneic HSC transplant before molecular/clinical evidence of relapse. Stem cell assays reveal interpatient heterogeneity of JMML LSCs, which are present in, but not confined to, the phenotypic HSC compartment. RNA sequencing of JMML LSC reveals up-regulation of stem cell and fetal genes (HLF, MEIS1, CNN3, VNN2, and HMGA2) and candidate therapeutic targets/biomarkers (MTOR, SLC2A1, and CD96), paving the way for LSC-directed disease monitoring and therapy in this disease.


  • Open Access

    H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells

    by Laura Godfrey, Nicholas T. Crump, Sorcha O’bYrne, I-Jun Lau, Siobhan Rice, Joe R. Harman, Thomas Jackson, Natalina Elliott, Gemma Buck, Christopher Connor, et al.

    MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer–promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.


  • Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs

    by Sorcha O’bYrne, Natalina Elliott, Siobhan Rice, Gemma Buck, Nicholas Fordham, Catherine Garnett, Laura Godfrey, Nicholas T. Crump, Gary Wright, Sarah Inglott, et al.

    By comparing fetal and adult B-lymphopoiesis, the authors identify a prepro–B-cell subset in humans that marks the origin of B-cell lineage commitment in utero.


  • Open Access

    A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway

    by Christopher C.T. Sng, Sorcha O'BYrne, Daniil M. Prigozhin, Matthias R. Bauer, Jennifer C. Harvey, Michelle Ruhle, Ben G. Challis, Sara Lear, Lee D. Roberts, Sarita Workman, et al.


  • Open Access

    High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans

    by Anindita Roy, Vojtech Bystry, Georg Bohn, Katerina Goudevenou, Tomas Reigl, Maria Papaioannou, Adam Krejci, Sorcha O'BYrne, Aristeidis Chaidos, Andrea Grioni, et al.


  • Open Access

    MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia

    by Jon Kerry, Laura Godfrey, Emmanouela Repapi, Marta Tapia, Neil P. Blackledge, Helen Ma, Erica Ballabio, Sorcha O’bYrne, Frida Ponthan, Olaf Heidenreich, et al.